Novavax: Mertens names the time frame for Stiko recommendation on TV - "side effects" probably like with Biontech/Moderna
Created: 01/29/2022, 11:07 am
By: Maximilian Kettenbach
Novavax recommendation expected: Stiko boss Thomas Mertens.
© Stefan Boness/Ipon/Imago
The first doses of the Novavax vaccine should be available in Germany by the end of February.
What's missing: The Stiko recommendation.
Now the chairman comments on the current status.
Munich - The next "helper" to push the end of the corona pandemic is ready.
The chairman of the Standing Vaccination Committee (Stiko), Prof. Thomas Mertens, announced on RTL that the protein-based vaccine "Novavax" would be recommended by the end of February.
"One can certainly expect a recommendation - whatever that looks like." He hopes that this will happen in time before the vaccine is available.
The federal government has already ordered 3.25 million doses of Novavax and wants to make some of them available by February 21st.
Despite "temporary side effects" - similar to the mRNA-based vaccines from Biontech/Pfizer and Moderna - Mertens considers the vaccine to be safe: "I don't think the vaccine poses a particular safety problem and I hope so." Study data would however, are still missing, as Mertens explains to RTL / ntv.
For example, the effect for certain groups such as the elderly or pregnant women “cannot be properly assessed”.
Mertens did not want to specify at this point in time whether the Stiko recommendation will only apply to certain groups.
More here soon.
